Announced
Synopsis
Fosun Pharma, a healthcare group in China, terminated the $158m acquisition of a 60% stake in OncoCare, a service provider of cancer treatment centers. Since the deal involved “a series of preliminary factors” that both parties could not fulfil before the due date on October 30, the two parties decided to terminate the transaction.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.